Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study

BMJ

Volumn 343, Issue 7814, 2011, Pages

  Schmidt, Morten ^a   Christiansen, Christian F ^a   Mehnert, Frank ^a   Rothman, Kenneth J ^b,c   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b RTI HEALTH SOLUTIONS   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXIBUPROFEN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETODOLAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; ROFECOXIB; TOLFENAMIC ACID; VALDECOXIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHILD; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DENMARK; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCHOOL CHILD; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PROSPECTIVE STUDY; REGISTER; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2 INHIBITORS; DENMARK; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; YOUNG ADULT;

EID: 79960089980     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d3450     Document Type: Article

References (30)

1. Laine L. The gastrointestinal effects of non-selective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002;32:25-32. (Pubitemid 36055618)
2. Whelton A. Renal aspects of treatment with conventional non-steroidal antiinflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110:33S-42S.
3. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82:85-94. (Pubitemid 44895440)
4. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
6. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6. (Pubitemid 40344379)
7. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
8. Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure - five more years. N Eng J Med 2004;351:2437-40. (Pubitemid 40485996)
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
10. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296:1619-32. (Pubitemid 44511609)
11. De Caterina R, Ruigómez A, Rodríguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med 2010;170:1450-5.
12. Ehrenstein V. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010;2:273-9.
13. Danish Medicines Agency. Reimbursement of medicines. www.dkma.dk.
14. Guidelines for treatment of atrial fibrillation in primary care in Denmark. [In Danish]www.laegehaandbogen.dk/default.aspx?document=1560.
15. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9. (Pubitemid 44816920)
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8. (Pubitemid 29299976)
17. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol 2008;51:779-86. (Pubitemid 351253742)
18. Badhwar N, Scheinman MM. Atrial fibrillation after atrial flutter ablation: is atrial fibrillation the primary arrhythmia? J Cardiovasc Electrophysiol 2008;19:1151-2.
19. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004;164:1993-8. (Pubitemid 39390555)
20. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992;135:1019-28.
21. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21. (Pubitemid 28274844)
22. Thomsen RW, Riis A, Munk EM, Norgaard M, Christensen S, Sorensen HT. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006;101:2704-10. (Pubitemid 44902639)
23. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
24. Van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. J Am Coll Cardiol 2004;44:2117-24. (Pubitemid 39585198)
25. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
26. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009;169:1677-83.
27. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531-9. (Pubitemid 30471029)
28. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology . 3rd ed. Lippincott Williams and Wilkins, 2008.
29. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303. (Pubitemid 43797117)
30. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92. (Pubitemid 41408600)